3,0
16. Juni 2012
Aktueller Mitarbeiter, mehr als 3 Jahre
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
- very diverse product portfolio (Renal, Nutrition, Hemophilia, Oncology etc) and are all acute care based hence higher margins - company employees and management truly believe in saving and sustaining lives - R&D spend of $1B annually - good corporate citizen and cares for employees
Kontras
- very profitable hence there is a lower sense of urgency in employees and management. Slow and fractured decision making - limited success with R&D spend in terms of new products or margin improvement. Low accountability - management team in general is old school and disconnected with rank and file. Employee surveys reflect this.